|
시장보고서
상품코드
2102430
습진 시장 규모, 점유율 및 성장 분석 : 치료법별, 질환별, 투여 경로별, 약제 클래스별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Eczema Market Size, Share, and Growth Analysis, By Treatment Type, By Disease Type, By Route of Administration, By Drug Class, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 습진 시장 규모는 2024년에 144억 9,000만 달러로 평가되며, 2025년 155억 4,000만 달러에서 2033년에는 28억 7,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 7.24%로 성장할 것으로 전망되고 있습니다.
전 세계 습진 시장은 특히 소아 및 젊은 성인을 중심으로 한 아토피성 피부염 유병률의 상승에 의해 크게 견인되고 있습니다. 도시화, 환경 오염, 기후 변화, 생활 방식의 변화와 같은 요인으로 인해 알레르겐 및 자극 물질에 대한 노출이 증가함에 따라 그 결과 습진 환자 수가 증가하고 있습니다. 진단율 상승에 따라 환자들은 효과적인 장기 관리 전략을 요구하게 되었으며, 혁신적인 외용 요법, 생물제제, 경구용 JAK 억제제 및 맞춤형 치료 솔루션에 대한 수요가 급증하고 있습니다. 표적형 생물제제 및 정밀 의학의 발전과 더불어, 면역 경로에 대한 이해가 심화됨에 따라 기존 코르티코스테로이드에 비해 전신적 위험이 감소된 매우 효과적인 치료법의 개발이 진행되고 있습니다. 이러한 임상 성과 향상에 대한 집중이 연구개발 및 임상 시험에 대한 투자 확대를 촉진하고 있으며, 결과적으로 시장의 지속적인 성장을 촉진하고 있습니다.
전 세계 습진 시장의 성장 요인
전 세계 습진 시장은 피부 건강에 대한 대중의 인식 제고로 인해 크게 지원되고 있습니다. 이로 인해 습진 증상에 대한 지식이 확산되고, 조기 진단 및 다양한 치료법의 지속적인 활용으로 이어지고 있습니다. 환자들은 치료되지 않은 습진이 삶의 질에 어떤 영향을 미치는지 더 깊이 인식하게 됨에 따라 효과적인 치료법을 적극적으로 찾게 되었고, 그 결과 제약사들은 제품 라인업을 확대하고 혁신적인 제형에 대한 투자를 진행하고 있습니다. 이러한 인식의 증대는 의료 종사자들이 포괄적인 치료 계획을 권장하는 계기가 되고 있으며, 전 세계 다양한 환자층에서 치료법이 지속적으로 채택됨에 따라 시장 성장을 더욱 촉진하고 있습니다.
전 세계 습진 시장의 제약 요인
전 세계 습진 시장은 주로 습진 치료제를 둘러싼 엄격한 규제 심사로 인해 개발 기간이 장기화되고, 규정 준수 비용이 증가한다는 큰 제약에 직면해 있습니다. 이러한 환경에서는 포괄적인 안전성 및 유효성 데이터의 필요성이 시장 진입 지연이나 제품 파이프라인 축소로 이어지는 경우가 많기 때문에 일부 제조사들은 신제품 출시를 주저하고 있습니다. 그 결과, 혁신이 저해되고 기존 치료법이 시장에서 강력한 입지를 유지하게 됩니다. 이러한 경쟁 압력의 부재는 제형 개선이나 가격 인하와 같은 잠재적인 진전을 방해하며, 전 세계 환자들의 수요가 증가하고 있음에도 불구하고 궁극적으로 시장 전체의 성장을 제한하게 됩니다.
전 세계 습진 시장 동향
전 세계 습진 시장에서는 제약사들이 유전체 분석 및 피부 미생물군집 연구를 활용함에 따라 개인 맞춤형 외용 제제로의 뚜렷한 추세가 나타나고 있습니다. 이러한 혁신적인 접근 방식을 통해 유효 성분을 특정 염증 경로에 맞추어, 개별 질환 표현형을 표적으로 하는 맞춤형 제품 개발이 가능해집니다. 피부과 전문의들이 환자의 유전자 프로필과 환경적 유발 요인에 기반한 맞춤형 치료를 점점 더 권장함에 따라 시장은 범용 연고에서 보다 맞춤화된 솔루션으로 전환되고 있습니다. 이러한 추세는 치료에 대한 만족도를 높일 뿐만 아니라, 프리미엄 가격 책정의 기회를 열어주고, 궁극적으로는 환자 및 보호자들 사이에서 브랜드 충성도를 함양하여 습진 치료 시장의 경쟁 구도를 재편하는 결과로 이어질 것입니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 습진 시장 규모 : 치료 유형별
세계의 습진 시장 규모 : 질환 유형별
세계의 습진 시장 규모 : 투여 경로별
세계의 습진 시장 규모 : 약제 클래스별
세계의 습진 시장 규모 : 유통 채널별
세계의 습진 시장 규모 : 최종사용자별
세계의 습진 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.08.05Global Eczema Market size was valued at USD 14.49 Billion in 2024 and is poised to grow from USD 15.54 Billion in 2025 to USD 2.87 Billion by 2033, growing at a CAGR of 7.24% during the forecast period (2026-2033).
The Global Eczema Market is significantly driven by the rising prevalence of atopic dermatitis, especially among children and young adults. Factors like urbanization, environmental pollution, climate change, and lifestyle changes have led to increased exposure to allergens and irritants, resulting in more eczema cases. As diagnosis rates rise, patients seek effective long-term management strategies, prompting a surge in demand for innovative topical therapies, biologics, oral JAK inhibitors, and tailored treatment solutions. Advances in targeted biologics and precision medicine, alongside a deeper understanding of immune pathways, facilitate the development of highly effective therapies with reduced systemic risks compared to traditional corticosteroids. This focus on enhanced clinical outcomes is prompting greater investment in research and clinical trials, thereby driving sustainable market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Eczema market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Eczema Market Segments Analysis
Global eczema market is segmented by treatment type, disease type, route of administration, drug class, distribution channel, end user and region. Based on treatment type, the market is segmented into topical therapies, systemic therapies, biologic therapies and phototherapy. Based on disease type, the market is segmented into atopic dermatitis, contact dermatitis, dyshidrotic eczema, seborrheic dermatitis, nummular eczema and other eczema types. Based on route of administration, the market is segmented into topical, oral and injectable. Based on drug class, the market is segmented into corticosteroids, calcineurin inhibitors, phosphodiesterase-4 (PDE4) inhibitors, janus kinase (JAK) inhibitors, biologics, antihistamines and other drug classes. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, dermatology clinics and homecare settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Eczema Market
The global eczema market is significantly propelled by the increasing public awareness surrounding skin health, which informs individuals about eczema symptoms, leading to earlier diagnosis and more consistent use of various therapeutic options. As patients become more cognizant of how unmanaged eczema affects their quality of life, they actively search for effective treatments, prompting manufacturers to broaden their product offerings and invest in innovative formulations. This heightened awareness also encourages healthcare providers to advocate for comprehensive care plans, further driving market growth through the sustained adoption of treatments among diverse patient populations around the world.
Restraints in the Global Eczema Market
The global eczema market faces significant restraints primarily due to rigorous regulatory scrutiny surrounding eczema therapeutics, which extends development timelines and increases compliance costs. This environment discourages some manufacturers from launching new products as the need for comprehensive safety and efficacy data often results in delayed market entry and constrains product pipelines. As a result, innovation is hampered, allowing existing treatments to maintain a strong market presence. This lack of competitive pressure stifles potential advancements in product formulation or price reductions, ultimately limiting the overall expansion of the market despite the rising demand from patients worldwide.
Market Trends of the Global Eczema Market
The global eczema market is witnessing a significant trend towards personalized topical formulations, as manufacturers harness genomic insights and skin microbiome research. This innovative approach enables the creation of tailored products that target individual disease phenotypes by matching active ingredients to specific inflammatory pathways. As dermatologists increasingly endorse personalized regimens informed by patient genetic profiles and environmental triggers, the market is shifting away from generic ointments to more customized solutions. This trend not only enhances therapeutic satisfaction but also paves the way for premium pricing opportunities, ultimately fostering brand loyalty among caregivers and reshaping the competitive landscape of eczema treatments.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Eczema Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Topical Therapies
- Systemic Therapies
- Biologic Therapies
- Phototherapy
Global Eczema Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Atopic Dermatitis
- Contact Dermatitis
- Dyshidrotic Eczema
- Seborrheic Dermatitis
- Nummular Eczema
- Other Eczema Types
Global Eczema Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Topical
- Oral
- Injectable
Global Eczema Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Corticosteroids
- Calcineurin Inhibitors
- Phosphodiesterase-4 (PDE4) Inhibitors
- Janus Kinase (JAK) Inhibitors
- Biologics
- Antihistamines
- Other Drug Classes
Global Eczema Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Eczema Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Dermatology Clinics
- Homecare Settings
Global Eczema Market Size & CAGR (2026-2033)
- North America (Treatment Type, Disease Type, Route of Administration, Drug Class, Distribution Channel, End User)
- US
- Canada
- Europe (Treatment Type, Disease Type, Route of Administration, Drug Class, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Disease Type, Route of Administration, Drug Class, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Disease Type, Route of Administration, Drug Class, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Disease Type, Route of Administration, Drug Class, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Leo Pharma A S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Galderma SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arcutis Biotherapeutics Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dermavant Sciences Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
